|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||16.87 - 17.55|
|52 Week Range||13.05 - 35.93|
|Beta (5Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.60|
Subscribe to Yahoo Finance Plus to view Fair Value for REPL
U.S. stock markets have been exceedingly volatile in 2022. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- are a prime example. Perhaps most interestingly, the Baker brothers bought large chunks of small-cap healthcare stocks Affimed (NASDAQ: AFMD), Cerus Corporation (NASDAQ: CERS), and Replimune Group (NASDAQ: REPL) in the most recent quarter.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Target enrollment of 180 patients reached in the CERPASS randomized controlled registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023 First 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma; data snapshot from these patients with six-month follow-up expected to be released in Q4 2022 RP2/3 update to be provided by year end,